BiotechTube

FYB206 + FYB206 + Keytruda

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non Small Cell Lung Cancer

Conditions

Non Small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer

Trial Timeline

Oct 3, 2024 → May 13, 2025

NCT ID
NCT06643117

About FYB206 + FYB206 + Keytruda

FYB206 + FYB206 + Keytruda is a phase 3 stage product being developed by Formycon AG for Non Small Cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT06643117. Target conditions include Non Small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Non Small Cell Lung Cancer were approved

Approved (20) Terminated (2) Active (0)
✅mouse nerve growth factorSun PharmaceuticalApproved
✅Pemetrexed + CarboplatinEli LillyApproved
✅pemetrexedEli LillyApproved
✅Osimertinib+cisplatin or carboplatin + pemetrexed EditAstraZenecaApproved
✅DurvalumabAstraZenecaApproved
✅Gefitinib + DocetaxelAstraZenecaApproved
✅OsimertinibAstraZenecaApproved

Hype Score Breakdown

Clinical
17
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06643117Phase 3Terminated

Competing Products

20 competing products in Non Small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
mRNA-1769ModernaPhase 2
0
BBP-398 with nivolumabBridgeBio PharmaPhase 1
18
Pemetrexed + CarboplatinEli LillyPhase 3
40
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
SelpercatinibEli LillyPre-clinical
26
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
40
NBTXR3NanobiotixPhase 1/2
33
PemetrexedEli LillyPre-clinical
26
pemetrexed + erlotinibEli LillyPhase 2
35
LY3295668 ErbumineEli LillyPhase 1
29
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37
pemetrexed + cisplatinEli LillyPhase 2
27
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
35
CetuximabEli LillyPhase 1
29
pemetrexed + docetaxelEli LillyPhase 3
40
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
35
PemCarbo + Pem onlyEli LillyPhase 3
36
TNG456 + abemaciclibEli LillyPhase 1/2
39
pemetrexed + cisplatinEli LillyPhase 1/2
24